Therapy to Elevate CD4 Counts in HIV-1 Disease: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Therapy to Elevate CD4 Counts in HIV-1 Disease (NCT01370018), a na phase 2, phase 3 study. The primary outcome is CD4/CD8 Ratio.

2. Clinical Question

These details define a narrow question about a biological treatment and a blood-based immune measure in a small pilot study. They do not describe a randomized comparison of treatment against placebo or usual care. Because the registry does not report the primary outcome value or a statistical analysis, the magnitude and precision of any observed change cannot be assessed from the record. The study rationale is not itself evidence that the proposed biological sequence occurred in participants.

3. Trial Design

The registry describes a completed study with a single-group model and enrollment of 4. Its phase is listed as both phase 2 and phase 3. Allocation is recorded as not applicable, and masking is listed as none. These features distinguish the study from a masked, randomized trial with a parallel control group. The record does not describe a comparator arm, so the treatment group cannot be contrasted with a concurrent untreated group in this study.

The listed intervention is alpha-1-proteinase inhibitor, a biological intervention. The arm description refers to HIV-1 infected individuals treated with alpha-1-proteinase inhibitor. The registry lists HIV disease as the condition. It does not report detailed eligibility criteria, participant baseline characteristics, treatment dose, administration schedule, or adherence information. Those details should not be inferred from the intervention name or the study rationale.

The recorded start is 2006-12, the primary completion is 2007-02, and the status is completed. The primary outcome is the CD4/CD8 ratio at 9 weeks after treatment initiation. The registry specifies a mean and standard deviation as the outcome summary, but the actual result values are not reported in the registry record.

A single-group design can describe measurements among treated participants, but it does not separate a treatment-associated change from other explanations such as natural variation, changes over time, or measurement variability. Without a control group, the design cannot directly estimate a treatment-versus-control contrast. The registry does not report a protocol-level explanation for the design, the enrollment target, or the basis for the stated enrollment. A sample-size justification is not reported in the registry record.

The listed phase classification should be read as a registry descriptor, not as evidence about the strength of the results. Likewise, the completed status means the study is recorded as completed; it does not indicate that its primary outcome was reported or that a treatment effect was established.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: HIV patients were receiving antiretroviral medication with adequate suppression of virus. No patients had previously received alpha-1 proteinase inhibitor treatment.

6. Primary Endpoint

The registry lists the primary outcome as CD4/CD8 Ratio, measured over 9 weeks after initiation of treatment.

The registered primary endpoint is the CD4/CD8 ratio, a continuous measure expressed as a ratio. The registry identifies the outcome summary as a mean with standard deviation and places measurement at 9 weeks after treatment initiation. The brief summary focuses on the proposed relationship between alpha-1-proteinase inhibitor levels and CD4 counts, while the registered primary endpoint is the ratio of CD4 to CD8 cells. These are related immune measures in the study rationale, but they are not interchangeable outcomes.

In general, a ratio endpoint represents one quantity relative to another. It can be useful when the relationship between the two components is of interest, rather than either component alone. Interpretation depends on the values and behavior of both components; the same ratio can arise from different combinations of numerator and denominator. A ratio result therefore does not, by itself, show which component changed.

The registry record does not report the observed mean, standard deviation, baseline value, change from baseline, or an inferential analysis for the primary endpoint. It also does not state whether the reported endpoint was intended to be analyzed as a final measurement or as a change over time. Consequently, the direction, size, and precision of the primary outcome cannot be described from the registry record. The timing identifies the planned assessment point, but it does not establish that measurements were available for every participant.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

Statistical methods are easiest to interpret when the outcome definition, comparison, and analysis are all clear. In this study, the registry identifies a continuous primary outcome: the mean CD4/CD8 ratio at 9 weeks after treatment initiation, with standard deviation as the stated measure of dispersion. It does not report an analysis for that endpoint. The general explanations below describe statistical concepts; they do not imply that the registry record used a particular method.

What does a mean describe?

General: A mean is an average that combines the observed values into one group-level summary. It can provide a compact description of a continuous outcome, but it does not show how individual values are distributed. A mean can be influenced by unusually high or low observations. For a small group, each observation may contribute substantially to the group summary. The registry names a mean as the endpoint parameter, but the numerical mean is not reported in the registry record.

What does a standard deviation describe?

General: A standard deviation describes the spread of individual observations around their mean. It is not the same as uncertainty in the estimated mean. Uncertainty about a mean is commonly described with a confidence interval or a standard error, which depends on the spread of observations and the amount of information available. The registry specifies standard deviation as the dispersion measure, but does not report its value, a standard error, or a confidence interval.

What would a confidence interval mean?

General: A confidence interval gives a range of values compatible with an estimate under the assumptions of the analysis. It communicates precision as well as direction and magnitude. A narrow interval indicates greater precision than a wide interval, but interpretation also depends on whether the estimate concerns a group mean, a change, or a contrast between groups. No confidence interval for the primary outcome is reported in the registry record, so the endpoint’s precision cannot be assessed.

What would a p-value mean?

General: A p-value describes how surprising the data would be under a specified statistical model and null hypothesis. It is not the probability that the null hypothesis is true, and it does not measure the size or importance of an effect. Its interpretation requires knowing the comparison, analysis, assumptions, and testing plan. The registry does not report a p-value or an analysis for the primary endpoint. A statistical conclusion cannot be reconstructed from the endpoint definition alone.

Why does the comparison matter?

General: A randomized control group can help distinguish treatment effects from changes that might have occurred over time without the intervention. In a single-group study, an observed change may have several explanations. A baseline measurement can offer context, but a before-and-after comparison is still vulnerable to time-related influences and other sources of bias. The registry records a single-group design and no like-for-like control comparison. It does not report a baseline outcome or a change estimate.

What is the role of a planning illustration?

General: A sample-size calculation can explore how many participants per arm might be needed under specified assumptions about the effect, variability, significance level, allocation, and statistical model. Such a calculation is a planning illustration, not an observed result, and it does not show the power achieved by a completed trial. The registry record does not report the trial’s own sample-size justification or statistical plan. Without a reported observed effect and variability, a trial-specific planning calculation cannot be interpreted from the registry record.

What can this record support?

The record establishes the registered endpoint, its timing, the single-group design, and the stated enrollment. It does not provide the outcome values or an inferential analysis. General statistical concepts can explain what summaries and comparisons would mean, but they cannot substitute for missing results. Any conclusion about the size, direction, uncertainty, or statistical significance of an endpoint result would require information not reported in the registry record.

10. Confidence Intervals for Each Arm

No two-arm comparison is shown for this trial, but each arm's mean can be given with a t-based 95% confidence interval computed from the posted mean, spread and number of participants.

R code and output

arm <- c("Alpha-1-Proteinase Inhibitor in HIV")
n   <- c(3)
m   <- c(0.44)
sp  <- c(0.3)
sd  <- sp      # posted standard deviations
for (i in seq_along(n)) {
  se <- sd[i] / sqrt(n[i]); h <- qt(0.975, n[i] - 1) * se
  cat(sprintf("CARM|%s|%d|%.3f|%.3f|%.3f|%.3f\n", arm[i], n[i], m[i], sd[i], m[i] - h, m[i] + h))
}

CARM  Alpha-1-Proteinase Inhibitor in HIV  3  0.440  0.300  -0.305  1.185

11. Multiplicity, Missing Data and Analysis Populations

Multiplicity concerns the possibility of drawing misleading conclusions when several outcomes, time points, subgroups, or statistical tests are examined. General: when many hypotheses are tested, the chance of at least one apparently notable result can increase unless the analysis plan accounts for the number and relationship of tests. A registry record can help readers identify planned outcomes and analyses, but interpretation also depends on whether a prespecified statistical plan is available and whether deviations are described.

The registry lists 1 outcome measure and 0 analyses. The primary endpoint is identified as the CD4/CD8 ratio at 9 weeks after treatment initiation. The record does not describe adjustment for multiple testing, a hierarchy of outcomes, subgroup analyses, interim analyses, or a statistical analysis plan. These matters are not reported in the registry record. The presence of a single listed outcome measure does not establish that no additional analyses were considered or performed.

Missing data affect both the analysis population and the interpretation of results. General: if outcome measurements are unavailable for some participants, the amount and reason for missingness can influence the estimate, particularly when missingness is related to participant characteristics or outcomes. A clear account typically identifies who was included in each analysis, how missing observations were handled, and whether sensitivity analyses were performed. The registry record does not report missing outcome data, an analysis population, or a method for handling missingness.

Because numerical outcome results and analysis details are absent, it is not possible to assess multiplicity control, the number of observations contributing to the endpoint, or the impact of missing data. The record’s enrollment figure should not be taken as confirmation that every participant contributed a primary outcome measurement.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The registry reports serious adverse events for the alpha-1-proteinase inhibitor group. It lists 4 participants at risk for serious adverse events and 0 affected by serious adverse events. It also lists 4 participants at risk for other adverse events and 0 affected by other adverse events. Deaths are listed as 0. These are the posted safety counts for the group in the registry record.

General: an adverse-event count describes what was recorded under the study’s reporting definitions and observation period. A zero count means no events of that category are listed in the posted results; it does not prove that an event is impossible or that no unreported event occurred. Interpretation also depends on follow-up duration, event definitions, completeness of reporting, and the size of the study.

The registry does not report event terms among the top serious-event terms. The study enrollment is small, so the absence of listed events should be read as a description of the recorded safety data, not as a precise estimate of risk. The record does not provide detailed event narratives, severity grades, timing, relatedness assessments, or a comparison group. The safety figures therefore cannot establish how event frequency compares with another treatment or with no treatment.

13. What the Result Does, and Does Not, Mean

The record establishes that the study was registered as a completed, single-group pilot study of alpha-1-proteinase inhibitor therapy in HIV-1 disease. It identifies the CD4/CD8 ratio at 9 weeks after treatment initiation as the primary outcome and specifies a mean with standard deviation as the planned summary. It also records serious adverse-event counts and deaths for the intervention group.

The record does not report the numerical primary outcome, a baseline-to-follow-up change, an effect estimate, a confidence interval, or a p-value. It therefore does not show the direction or size of an outcome change, or how precisely any change was estimated. The brief summary explains why the investigators were interested in treatment, but a proposed biological explanation is not a result. The registered primary endpoint is a ratio, while the summary’s rationale refers to alpha-1-proteinase inhibitor levels and CD4 counts; results for those measures are not reported in the registry record.

The single-group design also limits what could be concluded about causation. Without a concurrent control group, an observed change, if one were reported, could not be separated cleanly from changes over time or other influences. This limitation is about the design and remains distinct from the lack of outcome reporting.

The posted safety counts show no serious adverse events, other adverse events, or deaths recorded for the group. In general, zero recorded events in a small study do not demonstrate that risk is absent. The record does not provide comparative safety data or detailed event information.

Accordingly, the registry supports a description of the study’s purpose, design, endpoint, and posted safety counts. It does not support a conclusion that treatment did or did not change the primary outcome, nor does it establish comparative benefit or harm. The primary result and the information needed to assess its precision are not reported in the registry record.

14. Why This Trial Matters Statistically

Statistically, this study illustrates the difference between having a registered question and having a reported result that can answer it. The endpoint is clearly identified as the mean CD4/CD8 ratio at 9 weeks after treatment initiation, but the mean and its dispersion are not reported in the registry record. Without those values, readers cannot evaluate the outcome’s magnitude or variability. Without an inferential analysis, they also cannot assess uncertainty using a confidence interval or other estimate.

The single-group structure is another important feature. A treated-group measurement can describe what was observed in that group, but it does not provide a direct estimate of how outcomes compare with an untreated or otherwise controlled group. This distinction is central to interpreting evidence: a within-group observation and a treatment-versus-control effect answer different questions. Statistical modeling cannot remove the design limitation or supply a missing counterfactual comparison.

The study is described as a pilot and has a small stated enrollment. General statistical reasoning suggests that estimates from small studies can be sensitive to individual observations and may be imprecise. Yet actual precision cannot be judged without the outcome values and an uncertainty estimate. A planning illustration, if available, would not replace those observed results and would not show achieved power.

The record also demonstrates why registry completeness matters. Outcome definitions, time points, analysis populations, missing-data handling, and multiplicity plans help readers understand how results were generated and what scope of inference is justified. Several such details are not reported in the registry record. The absence of these details does not reveal what happened, but it limits what can be evaluated from the record.

The statistical importance is therefore primarily interpretive: design descriptors and a stated endpoint are not sufficient to establish an effect. Clear reporting of estimates, precision, analysis methods, and participant-level availability would be needed to assess the primary question.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several limitations specific to this study constrain interpretation. The registry describes a single-group design, with allocation recorded as not applicable and no like-for-like control comparison. This prevents a direct treatment-versus-control estimate. Any outcome change, were one reported, could also reflect time, measurement variation, or other influences. The registry does not report a baseline value or a change-from-baseline analysis for the primary endpoint.

The stated enrollment is 4, and the study is described as a pilot. A small study can provide limited information about the distribution of outcomes and may be sensitive to individual observations. The primary outcome values and dispersion are not reported, so the actual precision cannot be assessed. A sample-size justification and the protocol’s statistical plan are not reported in the registry record.

The registry identifies the endpoint as the CD4/CD8 ratio, whereas the brief summary describes a rationale involving alpha-1-proteinase inhibitor levels and CD4 counts. Numerical results for those biological measures are not reported in the registry record. The record also does not explain whether the endpoint was assessed as a final value or a change over time, or how missing measurements were handled.

Other details relevant to interpretation, including participant characteristics, eligibility criteria, dose, administration schedule, adherence, and the analysis population, are not reported in the registry record. The listed phase classification does not fill these gaps. The study’s completed status likewise does not establish that the primary result was posted. These limitations leave the registered question identifiable but the outcome evidence insufficient for quantitative assessment.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Therapy to Elevate CD4 Counts in HIV-1 Disease — NCT01370018.
• Registry record last updated 2021-09-28; status last verified 2021-08.
• Results first posted 2021-09-28.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

The registry describes a completed pilot study of alpha-1-proteinase inhibitor therapy in HIV-1 disease, with a single-group design and enrollment of 4. The phase is listed as phase 2 and phase 3. Allocation is not applicable, and masking is listed as none. The recorded start is 2006-12, with primary completion at 2007-02.

The primary endpoint is the mean CD4/CD8 ratio at 9 weeks after treatment initiation, with standard deviation specified as the dispersion measure. Numerical primary outcome results and analyses are not reported in the registry record. The posted safety counts list 0 serious adverse events, 0 other adverse events, and 0 deaths. A control comparison, detailed analysis plan, missing-data approach, and sample-size justification are not reported in the registry record.